Clinical Study
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
Table 1
Main eligibility criteria.
| Histologically confirmed advanced prostatic carcinoma | | Progression while on D or within 60 days after the last D dose | | A positive bone scan and a ≥25% increase in PSA in comparison with baseline | | New metastatic lesions revealed by a bone scan | | A ≥25% increase in bidimensionally measurable tumor mass | | ECOG PS of ≤2 | | Leukocytes ≥3000/mm3, haemoglobin ≥ 10 g/dL, platelets /mm3 | | Serum creatinine ≤ 2.0 mg/dL; serum bilirubin ≤ 2.0 mg/dL | |
|
|